Phase 1, Multicenter, Open-Label Study of the Antibody-Drug Conjugate TRPH-222 in Subjects With Relapsed and/or Refractory B-Cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2019
Price : $35 *
At a glance
- Drugs TRPH 222 (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Triphase Accelerator Corporation
- 01 Apr 2019 According to a Triphase Accelerator Corporation, the company announced that the first patient has been dosed for this study.
- 18 Oct 2018 Status changed from not yet recruiting to recruiting.
- 28 Sep 2018 New trial record